Systemic Quinolones and Risk of Retinal Detachment III: a Nested Case-control Study Using a US Electronic Health Records Database

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2022 Mar 15

PMID 35290480

Authors

Mohamed Kadry Taher

James A G Crispo

Yannick Fortin

Ryan Moog

Douglas McNair

Lise M Bjerre

Franco Momoli

Donald Mattison

Daniel Krewski

Affiliations

Soon will be listed here.

Abstract

Background: Quinolones are popular antibiotics that are known for their potency, broad coverage, and reasonable safety. Concerns have been raised about a possible association between quinolones and retinal detachment (RD).

Methods: We conducted a nested case-control study using electronic health records (EHR) from the Health Facts® Database. The initial cohort included all patients who were admitted between 2000 and 2016, with no history of eye disease, and had a minimum medical history of one year. Eligible cases comprised inpatients who were first admitted with a primary diagnosis of RD between 2010 and 2015. Each eligible case was matched without replacement to five unique controls by sex, race, age, and period-at-risk. We used conditional logistic regression to calculate RD risk, adjusting for exposure to other medications, and major risk factors.

Results: We identified 772 cases and 3860 controls. Whereas our primary analysis of all subjects revealed no quinolone-associated RD risk, elevated but non-significant risks were noted in African Americans (ciprofloxacin and levofloxacin), those aged 56-70 years old (moxifloxacin), and women (ciprofloxacin).

Conclusion: Our study did not identify an elevated RD risk within 30 days following systemic administration of quinolone antibiotics. Suggestions of increased risk observed in some population subgroups warrant further investigation.

Citing Articles

Use of fluoroquinolones and risk of rhegmatogenous retinal detachment: a retrospective cohort study using two nationwide representative claims databases.

Lin T, Wang J, Wang G, Huang Y, Chen M, Dong Y Front Pharmacol. 2024; 15:1414221.

PMID: 39723254 PMC: 11668581. DOI: 10.3389/fphar.2024.1414221.

Safety of fluoroquinolones.

Barberan J, de la Cuerda A, Tejeda Gonzalez M, Lopez Aparicio A, Monfort Vinuesa C, Ramos Sanchez A Rev Esp Quimioter. 2023; 37(2):127-133.

PMID: 38140798 PMC: 10945095. DOI: 10.37201/req/143.2023.

Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?.

Rusu A, Munteanu A, Arbanasi E, Uivarosi V Pharmaceutics. 2023; 15(3).

PMID: 36986665 PMC: 10056716. DOI: 10.3390/pharmaceutics15030804.

References

Bolon M . The newer fluoroquinolones. Med Clin North Am. 2011; 95(4):793-817, viii. DOI: 10.1016/j.mcna.2011.03.006. View

Wood F, Simpson S, Butler C . Socially responsible antibiotic choices in primary care: a qualitative study of GPs' decisions to prescribe broad-spectrum and fluroquinolone antibiotics. Fam Pract. 2007; 24(5):427-34. DOI: 10.1093/fampra/cmm040. View

Choi S, Lim H, Yim H, Park Y . Administration of oral fluoroquinolone and the risk of rhegmatogenous retinal detachment: A nationwide population-based study in Korea. PLoS One. 2018; 13(4):e0195563. PMC: 5896937. DOI: 10.1371/journal.pone.0195563. View

Etminan M . Pharmacoepidemiology II: the nested case-control study--a novel approach in pharmacoepidemiologic research. Pharmacotherapy. 2004; 24(9):1105-9. DOI: 10.1592/phco.24.13.1105.38083. View

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83. View

Szarfman A, Chen M, Blum M . More on fluoroquinolone antibiotics and tendon rupture. N Engl J Med. 1995; 332(3):193. View

Alves C, Penedones A, Mendes D, Marques F . A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment. Acta Ophthalmol. 2016; 94(5):e251-9. DOI: 10.1111/aos.12931. View

Gatti M, Bianchin M, Raschi E, De Ponti F . Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review. Eur J Intern Med. 2020; 75:60-70. DOI: 10.1016/j.ejim.2020.01.009. View

Lode H . Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. Am J Med. 2010; 123(4 Suppl):S26-38. DOI: 10.1016/j.amjmed.2010.02.004. View

10.

Go S, Hoyng C, Klaver C . Genetic risk of rhegmatogenous retinal detachment: a familial aggregation study. Arch Ophthalmol. 2005; 123(9):1237-41. DOI: 10.1001/archopht.123.9.1237. View

11.

Zhuo L, Farrell P, McNair D, Krewski D . Statistical methods for active pharmacovigilance, with applications to diabetes drugs. J Biopharm Stat. 2014; 24(4):856-73. DOI: 10.1080/10543406.2014.901338. View

12.

Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M . Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015; 80(2):285-93. PMC: 4541976. DOI: 10.1111/bcp.12611. View

13.

Cuzzolin L, Fanos V . Safety of fluoroquinolones in paediatrics. Expert Opin Drug Saf. 2003; 1(4):319-24. DOI: 10.1517/14740338.1.4.319. View

14.

Sultan Z, Agorogiannis E, Iannetta D, Steel D, Sandinha T . Rhegmatogenous retinal detachment: a review of current practice in diagnosis and management. BMJ Open Ophthalmol. 2020; 5(1):e000474. PMC: 7549457. DOI: 10.1136/bmjophth-2020-000474. View

15.

Appelbaum P, Hunter P . The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2001; 16(1):5-15. DOI: 10.1016/s0924-8579(00)00192-8. View

16.

Pasternak B, Svanstrom H, Melbye M, Hviid A . Association between oral fluoroquinolone use and retinal detachment. JAMA. 2013; 310(20):2184-90. DOI: 10.1001/jama.2013.280500. View

17.

Hall M, Finnoff J, Smith J . Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population. PM R. 2011; 3(2):132-42. DOI: 10.1016/j.pmrj.2010.10.003. View

18.

Douros A, Grabowski K, Stahlmann R . Safety issues and drug-drug interactions with commonly used quinolones. Expert Opin Drug Metab Toxicol. 2014; 11(1):25-39. DOI: 10.1517/17425255.2014.970166. View

19.

Noren G, Ralph Edwards I . Modern methods of pharmacovigilance: detecting adverse effects of drugs. Clin Med (Lond). 2009; 9(5):486-9. PMC: 4953463. DOI: 10.7861/clinmedicine.9-5-486. View

20.

Liu H . Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010; 33(5):353-69. DOI: 10.2165/11536360-000000000-00000. View